The te&nlqne of iotraeorcnary stentlng has achieved remarkable progress over the last fev years. Improved stent de@oyment tecboiqnes aad aptimizatIaa .1 pastpmmdaral maaagewat have draatatimIIy ~q~mved the safety af iatramnmag stent @ace-meat. At preseb 'be kteidew af early vessel dasare after ~~isevenlawerthanth3tafforsa~~a~~ most operators no lunger preserlbe aggresshe anbamgulatlon, bleeding wa~plieatlons are nneumnma.
Steotiog bas become an eatremely e&dive treatment firr abrupt or threatened vessel dosure or far say sabaptimal aitgh graplde result durlag mnventional aagbpWy.
Fortktmwe, large pmspective trials have demonstrated that its etlimq is Conventional balloon angioplasty, introduced >15 years ago, remains hampered by the persistence of two vexing problems: abrupt vessel closure during intervention and restenosis during follow-up. Despite improvement in operator skills and angioplasty material and a better understanding of tbe underlying pathologic processes, the incidence of these complications has not decreased Pharmacologic intervention with direct-acting thrombin inhibitors or glyeoprotein IIb/IlIa receptor inhibitors, or both, may prevent the occurrence of these adverse events in certain subgroups of patients (l-3). However, bleeding problems are more frequent with some of these new drugs; therefore, further optimization of drug dosage is currently being investigated. Mechanical intervention with intracoronary stems was introduced for human clinical investigation in 1986 (4). Their application should be considered as a second breakthrough technology in the geld of interventional cardiology. 'Ibe purpose of this article is to provrde a concise overview on this subject, including suggestions on present indications and postprocedural management.
Historical overview stenting with angiopiasty were initiated for primary and secondary restenosis prevention and for the treatment of saphenous vein graft narrowings and sudden or threatened vessel closure during angiopiasty. These randomized trials were started much earlier than studies comparing angiopiasty and coronary artery bypass grafting. At present, only primary restenosis prevention trials (Renestent I [Belgium/Netherlands] [9] and STRESS 1 [STent REStenosis Study] studies) [lo] have been completed and their data published. These data show favorable results for stenting, as will be discussed later.
History: part 3 (E&3/1994 to ?). If the second part of stent history was characterized by a clear reduction of procedurerelated complications and the completion of the first randomized trials, the third part is characterized by better stent deployment techniques and abolition of oral anticoagulation after the intervention. Goldberg (11) and Coiombo (12) and co-workers demonstrated by means of intravascular ultrasound that, with conventional implantation techniques, stem deploy q ent was suboptimal in up to 87% of cases with incorrect apposition of the device with the vascular surface. They therefore suggested additional high pressure noncompliant balloon angiopiasty to fully expand the stent. Although a relation between stent underexpansion and subacute thrombosis has never been clearly documented, several investigators (13), using ultrasound, progressively diminished and finally stopped their postintervention anticoagulation regimen and observed, simultaneously, very low closure rates with combined aspirin-ticiopidine treatment. French investigators (14) , in contrast, started a multicenter feasibility study on stenting without coumadin and without mandatory ultrasound in March 1992. In December 1992, after adding ticiopidine (250 mg twice daily) to postprocedural treatment with aspirin and low molecular weight heparin, they observed (15,16) a reduction in the incidence of subacute thrombosis from 10.4% (145 patients) to 1.3% (237 patients who received 1 month of subcutaneous low molecular weight heparin), 1.7% (523 patients who received 2 weeks of heparin) and 1.8% (491 patients who received 1 week of heparin). At present, full antiplatelet therapy, without additional subcutaneous heparin and without ultrasound guidance but with "blind" high pressure angiophrsty, has become routine clinical practice, mostly with the Pabnaz-Schatz and Giiturco-Roubin sterns but also in controlled safety trials such as the MUST (MUlticenter Stems Ticlopidme) study (using the "old" articulated Paimaz-Schatz stent). Today, elective and emergency stenting have become safe and feasible techniques in the hands of most interventionai cardiologists. This and a less steep learning curve (than that associated with other techniques such a, laser or atherectomy) explain the current success of coronary stems. Some investigators have introduced the current concept of endolumid vessel reconstruction which may imply greater than ordinary widening of coronary vessels by multiple or long stent impiantatio~ with the idea of improving long-term angiographic outcmne.
JACC Vol. 27, No. 4 March 15, 1996~757-65 Current Stent Types Stents can be distinguished by their type of delivery system (self-expanding, balloon-expandable), their composition (metallic-stainless steel, cobalt-based alloy or tantalum; biodegradable; polymeric) and their configuration (mesh structure; slotted tube; coil). Although most stents are placed definitively in coronary vessels, this list should be completed with the temporary retrievable bailout stent (RX Flow Support Catheter, Advanced Cardiovascular Systems) (17) . The foiiowing devices are currently used or still under clinical investigation in humans:
Wallstent (Schneider AG). This device, the first stent ever implanted in human coronary arteries, was used in Europe between 1986 and 1990. The self-expanding, wire mesh structure covers -20% of the vascular surface, making it the densest stent. This high metallic density has been held responsible for the high early vessel closure rate (20%), as reported in the European Registry in 1991 (7), and the stent was therefore withdrawn from clinical investigation in 1990 (7,18). However, since 1994, the Wallstent has gained new interest, especially for treatment of vein graft lesions, in which stents may be placed without predilarion, a strategy that may diminish the risk for distal emboiization. Controlled multicenter trials, examining the safety and efficacy of this stent for restenotic native and new-onset vein graft lesions, will soon be initiated in Europe and the U.S. The investigators believe that with better depioyment techniques, the incidence of subacute closure will be much lower.
Flexstoat (Gianturco-Roubin, Cook). Thii baiioon-expandable, stainless steel, single-wire structure has been used since 1987, initially only for the treatment of acute vessel closure during angiopiasty (19) . The largest experience has been gained' in the U. S., and observational trials (20) as well as risk factors analyses on adverse long-term outcome (21) have been published. Recently, favordbie results were reported in a small, randomized trial (22) of this stent for the treatment of suboptimal outcome after angiopiasty. These data will be discussed later. A new generation device with proximal and distal markers on the stent, capable of passing in large lumen GF guiding catheters, will soon be available.
Palmax-Sebata stent (Johnson & Johnson International Systems). This balloon-expandable, stainless steel, slotted tube device, introduced in 1987, is the most studied and widely used stent in the world. The Renestent I and STRESS I trials were carried out with this stent, and ongoing trials of secondary restenosis prevention, bailout and graft stenting are being performed with this device. The first-generation PalmazSchatz stem comprised, in addition to the short stem, two tubes co~ected by a metallic bridge (articuiated stent). This weaker part of the stent has been held responsible for restenosis by some investigators and the manufacturer has now released a spiral-like intersection that contains more metal but also makes it more rigid and less trackable (23) . A heparincoated form of this newly designed Pahnaz-Schatz stent wig be, used in future stent trials 'A "biliary" type of Pahnaz-Schata stem, with the same design but a slightly larger strut thickness, is available for implantation in large (>4.5 mm) saphenous vein grafts.
W&or stent (Medtronic Interventional Vascular). This balloon-expandable, helicoid coil, radiopaque (tantalum) device was the first of a new generation of stems released for clinical investigation in the early 1990s (24) . It has mainly been used for restenotic lesions, bailout situations and vein graft disease. A fibrin-coated and a new sma!! wave design stent (with more surface coverage) will be under evaluation.
Miem steot (Applied Vascular Engineering Inc., Richmond, Canada). This balloon-expandable, stainless steel stent is composed of different 4-mm segments of a continuous wire in zigzag design. Although this device has been widely used since 1994 in different settings, no large scale long-term angiographic follow-up data are available (25) . The stent is characterized by excellent trackability and is available in diierent lengths.
Cordis stem (Cordis). This balloon-expandable, tantalum, single-wire, helicoid stent is currently undergoing safety and efficacy evaluation in controlled studies (26) .
Multi Link stent (Advanced Cardiovascular Systems). This balloon-expandable, stainless steel device is characterized by multiple serial rings connected by several links. The stent is currently under evaluation.
Modalities of Stent Placement
Rok of intravascular t~ItmsomuL As mentioned pretiously, this technique had imposed the use of additional high pressure, noncompliant balloon angioplasty in tubular and sow coil stems that enabled the concept of no anticcX@ation-tirll antiplatelet therapy (K&27). At present, controlled trials (such as the STRUT [Stent Treatment Region assessed by Ultmsound Tomography] study) are examining the impact of ultrasound on further decision-making (more additional angioplasty) after high pressure angioplasty (28) . Current "blind high pressure" practice, which has resulted in very low subacute stent thrombosis rates, is probably as safe as ultrasound-guided stent placeacnt. Intravascular ultrasound, an essential research tool, does not seem imperative from this point of view. Completion of the STRUT (and similar) trials will elucidate whether ultrasound may improve the long-term efficacy of stenting by further reducing the incidence of restenosis.
Role of tidopiiae onfl other sew aatiplatekt ageats.
Ticlopidine, a thienopyridine derivative, has been shown to have a broad antiplatelet activity that is maximal after 3 days of treatment and 'that persists for t 10 days after its withdrawal (29) . Kiorically, this drug was used as premeditation for conventional angioplasty in patients with aspirin intolerance. Since the end of 1992, it has been used after stent implantation in a nonrandomized fashion with excellent results (15,16,?3 (32) . In view of the very low subacute stem thrombosis rates currendy being reported, the indication for these drugs after stenting is unclear. Future planned investigations may indicate categories of patients (large visible thrombus, acute myocardial inrarction) wbo will benefit from this treatment.
Role of transradiol approach. In 1994, Kiemeneij et al. (33) first described the use of the radial artery as an entry site for elective placement of the Palmaz-Schatz stent. In the era of full anticoagulation and amiplatelet therapy, this alternative approach was very promising because bleeding problems were virtually absent. At present, wilh the overall reduction in bleeding compliitions, the tramradial technique seems less attractive, although it remains an elegant technique in the hancij of experienced operators.
Technical aspects. Intracoronary stenting is technically more challenging than standard angioplasty. Stems are less trackable than modem angioplasty catheters and the stent delivery systems have a far larger profile. Incorrect judgment of the accessibility of the lesion is the major cause of deployment failure and stent embolization. Data are lacking, but one may assume that '5% of balloon-expandable s;ents are lost during implantation, mostly without sequelae as operators commonly retrieve in one movement guide wire, delivery system and guiding catheter in the descending aorta. Delivery systems with a stent-protective membrane, mostly used in the United States, appear safer but are less trackable. In general, if stent placement is intended, adequate backup (by an appropriate guiding catheter) and support (by use of extra support guide wires) is essential.
Specific measures may facilitate the intervention. Correct positioning is easier with radlopaque stems (Wiktor. Cordis stent) or with these delimited by double markers (bfii0, new Gianturco-Roubin stem). Overall, the self-expandmg Wallstent remains the most difhcult device to irDplR0t IXXectly beemw it lacks radiopacity and important shortening occurs during pullback of tbe protective membmne.
~nqmalIy, tubular stents may cause side branch closure and prchr&it the application of percutaneous coronary intervention if ostial disease is "present in these side branches. Reported data (34.35) show that closure occurs rarely (<5%) and that its axwrence, which appears to imply no clinical sequelae, is mostly related to the presence of ostial disease of the branch. Therefore, coil stems should be implanted in the main artery if intervention in large (>2-mm) side bran&s is intended 
Limitations of Standard Balloon Angioglasty
Angbgrapbic snceess and result. Angiographic success, detined as ~50% residual stenosis at the end of the intervention as assessed during off-line quantitative coronary angiographic analysis in the core laboratory, is not always present after an angioplasty that the operator has judged successful by visual assessment. Diierent success rates obtained after angioplasty are listed in Table 1 (9, (36) (37) (38) (39) (40) . Over the course of time, these rates have tended to increase and the discrepancy between qualitative and quantitative angiographic analysis has decreased with growing experience, insight into the utility and accuracy of quantitative angiographic analysis and the performance of randomized trials. The latier have contributed to a better execution of the angioplasty procedure, as operators try to optimize their angiographic results by conventional means. Even though we "do better than before," angioplasty will be unsuccessful in certain patients and suboptimal in others, perhaps causing persistence of angina in some patients or exposing others to a higher risk for restenosis. Different investigators (941-43) have shown that, independent of revasctdarization technique (angioplasty, directional atherectomy or stenting), an optimal angiographic result diminishes the risk for restenosis.
S&optimal an&graphic results. A suboptimal angiographic result after coronary angioplasty is typically caused by acute elastic recoil, residual plaque burden and dissection. In the absence of heavily calcified plaque (for which lesion pretreatment with rotational atherectomy is a valuable option), intracoronary stent placement scaffolds the vessel wall and reduces its acute elastic recoil more than does angioplasty (47) . This observation by Haude et al. (47) was confirmed in prospective studies such as the STRESS I trial, which demonstrated a higher immediate angiographic success rate (99.5% vs. 92.6%) and superior results (19 + 11% vs. 35 + 14% residual stenosis, mean 2 SD) with stenting (22). In a small randomized trial with 66 patients, Rodriguez et al. (22) showed that implantation of a Gianturco-Roubin stent after a subop timal result (residual stenosis ?40% 24 h after angioplasty) reduced the incidence of restenosis from 75.7% (if no further intervention was performed) to 21.2%.
Although these data suggest that unplanned stenting should be performed for suboptimal results after angioplasty, no clear residual stenosis cutoff value has been proposed. It seems reasonable to advise stent implantation (Palmaz-Schatz or Gianturco-Roubin device) for a residual stenosis >25%, as this value was obtained in the Etenestent I and STRESS I trial after stenting. However, if a residual stenosis ~20% can be obtained with conventional angioplasty, there is no rationale for additional stenting.
Therefore, in view of this "the bigger, the better" theory, angioplasty may require new device assistance to increase angiographic success and to improve suboptimal angiographic results.
Abrupt vessel elnsure. Vessel closure during angioplasty is unpredictable and still occurs with an unchanged nonnegligible incidence rate of 4.4% to 8.3% (44) . The immediate and long-term outcome of patients who experience abrupt vessel closure during angioplasty are impaired. Despite combined reangioplasty, thrombolysis and urgent bypass grafting, a 6% Abrupt ur threateued vesse1 clusure duriug aogioplasty. After their initial description of the stenting technique in 1987 (4), Sigwart et al. (48) reported a larger experience, restricted to bailout stenting, in 1988. Numerous observational trials with different stent types have since been reported (Table 2) (19, 21, (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) . These studies have shcwn high technical success rates but striking differences in the incidence of adverse events. Etetween 1986 and 1993, the incidence of subacute stent thrombosis and related myocardial infarction did not decrease. Recently, the French multicenter study on stenting without coumadm (14) reported, in the subgroup with rescue stenting, a 3.4% closure rate with the addition of t&pi&me to the incidence of death and 33% incidence of myocardial infarction have been reported (44) .
Restenosis. Restenosis, treated repeatedly by conventional angioplasty, is safe and efficient but also more expensive than primary stenting or even grafting (45) . Only their greater clinical need for repeat interjection, caused by reetenosis, discriminated patients treated with angioplasty from those who had undergone bypass grafting in all randomized trials that have compared these therapeutic options (46) . Similar rates of death and myocardial infarction with these therapies provide an ethical basis for further transcatheter coronaty therapies. However, new device assistance seems mandatory to further improve the immediate safety and the long-term efficacy of angioplasty by reducing the need for urgent or eleaive reintervention, or both.
Indications for Stenting
EECWOZlT ET AL. (44) . Although the results may seem promising, they were obtained in small series and in the hands of experienced operators. Repeat angioplasty and stenting remain the moSt commonly used and available techniques. Autoperfusion balloon angioplasty prolongs the intervention and has a nonnegligible failure rate that requires final crossover to stenting (44) . In contrast to the many observational trials on bailout stenting, only two randomized trials have compared stenting (Palmaz-Schatz) with prolonged autoperfusion balloon angioplasty. The TA!X II trial (Trial of Angioplasty and Stems in Canada) (64), a small study of 43 patients, found more clinical success (90% vs. 42%) and improved immediate angiographic results with stenting. The GRACE trial (Gianturco-Roubin stent Acute Closure Evaluation) (65) , designed in 1992 and using the Gianturco-Rcubm stent, has not yet reported results.
Akhough results of the GRACE trial are lacking, it may be concluded that stenting is a&ally the better technique for the management of acute or threatened closure during angioplasty. A wide spectmm of conditions, from &optimal angiographic results after angioplasty to a large protruding disseetion with impaired dii flow or total vessel closure, may benefit from stent placement. Because large randomized trials are lacking, the operator sltoukl choose: the device with which he is most familiar and use high pressure angioplasty, depending on the dent type (66) . In cases of extreme vessel tortuosity or small vessel size. membrane-protected stems or the trackable Micro stent can be considered. Even the presence of thrombus in bailout situations does not seem to be a contraindiition to stenting as Sutton et al. (21) found that it was not retained as a risk factor for adverse events in a multivariate analysis. Vety small vessel size (<U mm) is one of the last remaining absolute contraindications to stenting. However, patients with such vessels are also poor surgicd candidates and revascuk&ation should be carefuRy considered before percutaneous intervention. Tii0pidine may be adminhtered before angioplasty in order to obtain thii drt@ full et&icy during the intervention.
Re7 §mo&afteraIsglapIaaty*primary~~ Four trials comparing stenting and angioplasty for new lesions in native cor0nary arteries have been conducted with the Pahnaz-Schatz stent; one smaller pilot study has been performed with the Wiior stent (9,1O,67-69).
IntheRenestentI(n=52O)and!5TRESI(n=410)tria& patients with new discrete (length <IS mm) Iesions in large (Smm) native conmary arteries were rand0mii between 1991 and 1993 in 4g centers in the IJ. S. and Europe. At 6m0ntb follow-up (9,10x the essential cxmc%om were that elective implantatkm of an articulated Palmaz-Schatz stent inducedasustai&~bene6twithareduction0f tberestenosisrateby~~andlessneedforrepeatinterven-tion than that obtained with angioplasty. Further chnieal EECKHOlJT Table 2 .
follow-up during 1 year in the Benestent I group (70) showed that these conclusions could be maintained. Despite these positive results, there were several problems. 1) The patients, to whom the preceding restrictive criteria apply, are only a small part of the general population of patients with coronary artery disease. 2) Patients who receiT:ed stents had received full anticoagulation, which caused a longer hospital stay and a higher incidence of bleeding problems with a need for surgical repair or blood transfusion (7.3% for STRESS I and 13.5% for Benestent I). 3) Only the Benestent I trial showed sustained clinical benefit with stenting. The STRESS I investigators reported a tendency toward benefit that prompted these investigators to proceed with further randomization (STRESS II). The START trial (STent versus Angioplasty Restenosis Trial) is a Spanish multicenter study that, like STRESS, included patients with unstable and multivessel disease (67) . The study is about to lx completed and results, which are similar to those of the preceding trials, will soon be published. A fourth, smaller, study, the Canadian TASC I study, found a 7% rate of myocardial infarction in patients with stents related to a historical problem of subacute closure (68) .
In contrast to the favorable results observed with the Palmaz-Schatz stent, primary Wiktor stenting of the right coronary artery did not show any clinical or angiographic advantage over standard angioplasty in a pilot study conceming 84 patients (69) . At present, no further trials with this or other (than the Palmaz-Schatz) stents are planned.
A pilot phase with 200 patients showed the safety (no case of stent thrombosis) of a new, heparin-coated Pahnaz-Schatz stent with a modified spiral articulation. This stent will be used in the Benestent II trial, which will investigate the efficacy of primary stenting in multivessel disease (71) , evaluate major adverse clinical and angiographic events and perform a quality of lie analysii and a financial comparison.
Seco&ry restenosis m Stent placement has been performed for the treatment of resten& lesions since 1986, and a limited number of observational studies with different stent types (Table 3) (8, 24, 21, (72) (73) (74) (75) (76) have been published. Many of these series, which typically are not focused on secondary stenosis prevention, appear rather outdated. A nonnegligible incidence of subacute thrombosis and restenosis rates, varying between 17% and 39%, has been reported. Nevertheless, restenotic lesions have a different pathologic substrate from that of new stenotic lesions and may predispose to a higher incidence of a second restenosis. Savage et al. (75) reported a higher restenosis rate after stenting of restenotic versus new lesions. Thus, the favorable results of certain primary restenosis prevention trials cannot be extrapolated to secondary restenosis prevention and it is unclear whether stenting is superior to angioplasty for restenotic lesions.
The REST trial (RIGstenosis STent study), initiated in 1991 in Germany and currently extended to several European centers (77) , investigates this issue in a randomized fashion. A first answer to this important topic is expected shortly.
Saphenous vein graft stenting. Conventional angioplasty of vein graft lesions is limited by the risk of distal embolization of plaque during intervention and by a high incidence of restenosis (78) . Fycept for stenting, new technology has been very disappointing and the only randomized trial (CAVEAT II, Coronary Andoplasty versus Excisional Atherectomy Trial) on vein graft lesions showed similar restenosis rates and a higher incidence oi periprocedural complications with directional atherectomy in comparison with angioplasty (40) . Stenting of such lesions has been performed since 1986, and the experience of several centers has been reported (Table 4) (79-90). Even before the era of ultrasound and high pressure angioplasty, stenting in vein graft lesions was characterized by very low subacute stent thrombosis rates whereas a 30% incidence rate of restenosis may be expected during follow-up. It is currentIy unclear whether stenting results in less distal embolization during intervention. This issue as well as the impact of stenting on restenosis will be addressed in the SAVED trial (Stent versus balloon Angioplasty for aorto- and certain devices have an "ant&stenosis" effect in selected patients. Most of these patients are also good surgical candidates, a group that excludes patients with distal lesions in very small vessels.
Stents will not eliminate the restenosis problem. and a persistent restenosis rate of 10% to 15% should be expected with the best of current devices. However, it is a first step in restenosis prevention and may, in the future, be part of a more global approach to preventing restenosis that may also include stent irradiation and the use of local drug delivery or gene therapy with the use of polymeric or biodegradable stems as the vehicle for application.
At present. hecause the learning curve is short and because coronq stent placement is the most efficient means of reversing acute vessel closure during angioplasty, the ability to use these devices is mandatory in every modem catheterization laboratory.
